

BERG INTERROGATIVE BIOLOGY® PLATFORM EXECUTIVE SUMMARY

- BERG Interrogative Biology® is an industry-pioneering platform at the intersect of technology and medicine, developed by the first biotech to advance AI in drug/diagnostics discovery.
- The platform has been used by major partners in Government: (DoD, VA, Genomics England), Industry: (AZ, Boehringer Ingelheim, Sanofi, Beckton Dickinson), and Academia : (Harvard, Stanford, Oxford, etc.).
- The process is powered by patient-derived data, biological modeling, and AI to develop therapeutics and diagnostics assets.
- Interrogative Biology® insight and findings are typically first-in-class molecular entities with an attractive landscape for FTO and IP strategies.
- The multi-omics insights augment genomic insights and create a more robust narrative on patient biology to improve time and predictive efficiency to drug and diagnostic development, and support to healthcare partners from the payer/provider base.

VALIDATION OF THE BERG PLATFORM


Collaborations with Big Pharma, Academia & Government

- Sanofi Pasteur
- Becton Dickinson
- Boehringer Ingelheim
- AstraZeneca



- Pancreatic Cancer
- Breast Cancer Biomarkers
- NAFLD/ NASH/ Liver Fibrosis
- MOA of Therapeutic Compounds
- Discovery of Novel Therapeutic Compounds
- Prostate Cancer Diagnostics
- Lupus Biomarkers
- Parkinson's Disease Biomarkers
- Alzheimer's Disease Biomarkers

PLATFORM: PROCESS AND HIGHLIGHTS



- The uniqueness of the platform lies in the integration of several key elements including perturbation, omics & AI expertise.
- The platform is data agnostic and hypothesis independent.
- There are multiple patents protecting the interrogation of cell-based assays through the lens of molecular causality.

COMMERCIAL VALUE

Globally, pharmaceutical research and development spends more than \$186 billion dollars annually in a hypothesis driven manner. BERG's Interrogative Biology® platform is positioned to streamline efforts putting patient biology at the forefront of discovery, increasing efficiency of translation in development and triaging targets, causally selecting effective biomarkers, and prioritizing assets upfront to increase market value in a data driven manner.